Hybridoma Platform

Creative Biolabs provides a full range of services based on our matured hybridoma platform. Our featured services involve the custom monoclonal antibody production, from gene expression or peptide synthesis to antibody purification and labeling. We have the capacity of producing antibodies in either research quantities or in large scale for diagnostic industry. Importantly, we can produce monoclonal antibodies within 70 days. Creative Biolabs also has the expertise in handling antigen insufficiency and targeting very impure antigens.

Hybridoma technology is a method for the long-lasting production of large-scale monoclonal antibodies. The technology is based on the forming of hybrid cell line, which are immortalized cell derived from the fusion of specific antibody-producing B lymphoblast with myeloma. The general development of hybridoma cells starts by immunizing animals with target antigen to induce immune response. The splenocytes are then harvested from immunized animals. B cells that produce specific antibodies binding to the target antigen are isolated and in turn fused with a kind of immortal cancer cells (e.g. myeloma), which is able to grow in tissue culture and do not express antibodies by themselves. The finally produced fusion cells are known as hybridoma cells, which can be cultured through media and express monoclonal antibodies specific recognize the target antigen.

Through the development of hybridoma platform, the production and utilization of monoclonal antibodies have become more and more popular. Currently, monoclonal antibodies are widely applied in numerous areas, which involve in the prevention, diagnosis and treatment of disease. They are also important tools for the investigation of biochemistry, molecular biology and medicine. Monoclonal antibodies (mAbs) are made by identical immune cells and able to bind the same epitope for specific target antigen. Through this specificity, mAbs serve to detect or purify their specific binding target, which can be helpful in identifying cell surface markers or recognizing cancer cell receptors. For instance, the specific binding ability of a particular monoclonal antibody can be used to distinguish the subsets of B cells and T cells which then contributes to the identification of various leukemia types. In addition, combine with other advanced techniques available in Creative Biolabs, such as bispecific technique, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR), the extended application of mAbs can further assist the development of cancer therapeutic.

Creative Biolabs has extensive experience in the application of hybridoma platform. Our scientists are confident in offering the best services and products through our hybridoma platform. Besides, we prepare mono-specific polyclonal antibodies by ligand affinity chromatography. We also do epitope prediction, peptide synthesize, protein expression, polyclonal or monoclonal antibody production as well as antibody purification from cell culture, ascites fluid or whole serum.

Hybridoma Platform

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: